Status:
RECRUITING
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Conditions:
Cervical Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizi...
Detailed Description
Early stage cervical cancer is managed surgically while chemoradiation is the mainstay for treatment of bulky or advanced stage disease. The primary aim of post-treatment surveillance is to detect ear...
Eligibility Criteria
Inclusion
- 18 years of age or older on day of signing informed consent
- New diagnosis of cervical cancer
- Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee
Exclusion
- Women who are pregnant
Key Trial Info
Start Date :
May 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 15 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04743674
Start Date
May 3 2024
End Date
January 15 2027
Last Update
May 14 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Melissa Knutsen
Chapel Hill, North Carolina, United States, 27599
2
Kamuzu Central Hospital
Lilongwe, Malawi